Burimamide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Burimamide
Skeletal formula
Space-filling model
Identifiers
CAS number 34970-69-9 YesY
PubChem 3032915
ChemSpider 2297780 YesY
UNII TN5A4OD2TV YesY
KEGG C07448 YesY
ChEMBL CHEMBL12160 YesY
Jmol-3D images Image 1
Properties
Molecular formula C9H16N4S
Molar mass 212.32 g/mol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 YesY (verify) (what is: YesY/N?)
Infobox references

Burimamide is an antagonist at the H2 and H3 histamine receptors. It is largely inactive as an H2 antagonist at physiological pH,[1] but its H3 affinity is 100x higher. It is a thiourea derivative.

Burimamide was first developed by scientists at Smith, Kline & French (SK&F; now GlaxoSmithKline) in their intent to develop a histamine antagonist for the treatment of peptic ulcers.[2] The discovery of buriamide ultimately led to the development of cimetidine (Tagamet).[2]

See also[edit]

References[edit]

  1. ^ Clayden, Jonathan; Greeves, Nick; Warren, Stuart; Wothers, Peter (2001). Organic Chemistry (1st ed.). Oxford University Press. p. 205. ISBN 978-0-19-850346-0. 
  2. ^ a b "Tagamet®: Discovery of Histamine H2-receptor Antagonists". National Historic Chemical Landmarks. American Chemical Society. Retrieved June 25, 2012.